Product Brochure

NAD+ Booster NMNH Proved for Safety and Efficacy

Overview

NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.

EffePharm's UthPeak™ NMNH has completed toxicology and efficacy tests, affirming its safety and health potential in the dietary supplement market. Our animal tests highlight its anti-aging, anti-fatigue, and cardiovascular health benefits. Clinical trials on humans are currently underway. Partnering with Double Wood, the first UthPeak™ NMNH product has launched on Amazon. Download the flyer below to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”